Search

Your search keyword '"Fazio, Francesca"' showing total 5 results
Start Over Author "Fazio, Francesca" Publisher frontiers media sa
5 results on '"Fazio, Francesca"'

1. Immunogenicity of SARS-CoV-2 vaccination in patients undergoing autologous stem cell transplantation. A multicentric experience

Author

Autore, Francesco, primary, Stirparo, Luca, additional, Innocenti, Idanna, additional, Papa, Elena, additional, Marchesi, Francesco, additional, Togni, Chiara, additional, Mariani, Sabrina, additional, Torrieri, Lorenzo, additional, Salvatori, Martina, additional, Fazio, Francesca, additional, Metafuni, Elisabetta, additional, Giammarco, Sabrina, additional, Sora, Federica, additional, Falcucci, Paolo, additional, Ferrari, Antonella, additional, Trisolini, Silvia Maria, additional, Capria, Saveria, additional, Tafuri, Agostino, additional, Chiusolo, Patrizia, additional, Sica, Simona, additional, and Laurenti, Luca, additional

Published
2022
Full Text
View/download PDF

2. GAS6/TAM signaling pathway controls MICA expression in multiple myeloma cells

Author

Kosta, Andrea, primary, Mekhloufi, Abdelilah, additional, Lucantonio, Lorenzo, additional, Zingoni, Alessandra, additional, Soriani, Alessandra, additional, Cippitelli, Marco, additional, Gismondi, Angela, additional, Fazio, Francesca, additional, Petrucci, Maria Teresa, additional, Santoni, Angela, additional, Stabile, Helena, additional, and Fionda, Cinzia, additional

Published
2022
Full Text
View/download PDF

3. Immunogenicity of SARS-CoV-2 vaccination in patients undergoing autologous stem cell transplantation. A multicentric experience

Author

Autore, Francesco, Stirparo, Luca, Innocenti, Idanna, Papa, Elena, Marchesi, Francesco, Togni, Chiara, Mariani, Sabrina, Torrieri, Lorenzo, Salvatori, Martina, Fazio, Francesca, Metafuni, Elisabetta, Giammarco, Sabrina, Sora', Federica, Falcucci, Paolo, Ferrari, Antonella, Trisolini, Silvia Maria, Capria, Saveria, Tafuri, Agostino, Chiusolo, Patrizia, Sica, Simona, Laurenti, Luca, Sora, Federica (ORCID:0000-0002-9607-5298), Chiusolo, Patrizia (ORCID:0000-0002-1355-1587), Sica, Simona (ORCID:0000-0003-2426-3465), Laurenti, Luca (ORCID:0000-0002-8327-1396), Autore, Francesco, Stirparo, Luca, Innocenti, Idanna, Papa, Elena, Marchesi, Francesco, Togni, Chiara, Mariani, Sabrina, Torrieri, Lorenzo, Salvatori, Martina, Fazio, Francesca, Metafuni, Elisabetta, Giammarco, Sabrina, Sora', Federica, Falcucci, Paolo, Ferrari, Antonella, Trisolini, Silvia Maria, Capria, Saveria, Tafuri, Agostino, Chiusolo, Patrizia, Sica, Simona, Laurenti, Luca, Sora, Federica (ORCID:0000-0002-9607-5298), Chiusolo, Patrizia (ORCID:0000-0002-1355-1587), Sica, Simona (ORCID:0000-0003-2426-3465), and Laurenti, Luca (ORCID:0000-0002-8327-1396)

Abstract

COVID-19 disease has a strong impact on hematological patients; those receiving autologous hematopoietic stem cell transplantation (aHSCT) represent a particularly vulnerable group, in which the effectiveness of vaccination is very variable. Chiarucci et al. showed that patients affected by non-Hodgkin lymphoma (NHL) and treated with rituximab experienced a lower rate of immunization against SARS-CoV-2 (54%), as well as significantly lower IgG antibody titers. In our multicenter retrospective observational study, we included 82 patients who underwent aHSCT, divided into two groups: 58 patients vaccinated after aHSCT (group A) and 24 vaccinated before getting transplantation (group B). In group A, 39 (67%) patients had positive serology, and the rate of positivity increased with time after aHSCT. In the subgroup of patients with NHL the administration of rituximab predicted negative serology, particularly when administered in the 6 months before vaccination (13% response rate). Patients affected by plasma cells had a higher rate of positivity (83% overall), independently of the time to aHSCT. In group B, no patient who initially showed positive serology became negative after transplantation, so the aHSCT did not affect the response to the vaccination. Our study confirmed the role of rituximab as a negative predictor of response to SARS-CoV-2 vaccination, whereas the conditioning and transplantation procedure itself seemed to be less important.

Published
2022

4. Physicians’ Perceptions of Clinical Utility of a Digital Health Tool for Electronic Patient-Reported Outcome Monitoring in Real-Life Hematology Practice. Evidence From the GIMEMA-ALLIANCE Platform

Author

Efficace, Fabio, primary, Patriarca, Andrea, additional, Luppi, Mario, additional, Potenza, Leonardo, additional, Caocci, Giovanni, additional, Tafuri, Agostino, additional, Fazio, Francesca, additional, Cartoni, Claudio, additional, Petrucci, Maria Teresa, additional, Carmosino, Ida, additional, Moia, Riccardo, additional, Margiotta Casaluci, Gloria, additional, Boggione, Paola, additional, Colaci, Elisabetta, additional, Giusti, Davide, additional, Pioli, Valeria, additional, Sparano, Francesco, additional, Cottone, Francesco, additional, De Fabritiis, Paolo, additional, Ardu, Nicolina Rita, additional, Niscola, Pasquale, additional, Capodanno, Isabella, additional, Leporace, Anna Paola, additional, Pelliccia, Sabrina, additional, Lugli, Elisabetta, additional, La Sala, Edoardo, additional, Rigacci, Luigi, additional, Santopietro, Michelina, additional, Fozza, Claudio, additional, Siragusa, Sergio, additional, Breccia, Massimo, additional, Fazi, Paola, additional, and Vignetti, Marco, additional

Published
2022
Full Text
View/download PDF

5. Physicians' Perceptions of Clinical Utility of a Digital Health Tool for Electronic Patient-Reported Outcome Monitoring in Real-Life Hematology Practice. Evidence From the GIMEMA-ALLIANCE Platform

Author

Fabio Efficace, Andrea Patriarca, Mario Luppi, Leonardo Potenza, Giovanni Caocci, Agostino Tafuri, Francesca Fazio, Claudio Cartoni, Maria Teresa Petrucci, Ida Carmosino, Riccardo Moia, Gloria Margiotta Casaluci, Paola Boggione, Elisabetta Colaci, Davide Giusti, Valeria Pioli, Francesco Sparano, Francesco Cottone, Paolo De Fabritiis, Nicolina Rita Ardu, Pasquale Niscola, Isabella Capodanno, Anna Paola Leporace, Sabrina Pelliccia, Elisabetta Lugli, Edoardo La Sala, Luigi Rigacci, Michelina Santopietro, Claudio Fozza, Sergio Siragusa, Massimo Breccia, Paola Fazi, Marco Vignetti, Efficace, Fabio, Patriarca, Andrea, Luppi, Mario, Potenza, Leonardo, Caocci, Giovanni, Tafuri, Agostino, Fazio, Francesca, Cartoni, Claudio, Petrucci, Maria Teresa, Carmosino, Ida, Moia, Riccardo, Margiotta Casaluci, Gloria, Boggione, Paola, Colaci, Elisabetta, Giusti, Davide, Pioli, Valeria, Sparano, Francesco, Cottone, Francesco, De Fabritiis, Paolo, Ardu, Nicolina Rita, Niscola, Pasquale, Capodanno, Isabella, Leporace, Anna Paola, Pelliccia, Sabrina, Lugli, Elisabetta, La Sala, Edoardo, Rigacci, Luigi, Santopietro, Michelina, Fozza, Claudio, Siragusa, Sergio, Breccia, Massimo, Fazi, Paola, and Vignetti, Marco

Subjects
Cancer Research, hematology, digital health, leukemia, lymphoma, Settore MED/15, patient-reported outcomes (PROs), digital health, hematology, leukemia, lymphoma, multiple myeloma, patient-reported outcomes (PROs), quality of life, symptoms, multiple myeloma, Oncology, quality of life, symptoms
Abstract

Digital health tools are increasingly being used in cancer care and may include electronic patient-reported outcome (ePRO) monitoring systems. We examined physicians’ perceptions of usability and clinical utility of a digital health tool (GIMEMA-ALLIANCE platform) for ePRO monitoring in the real-life practice of patients with hematologic malignancies. This tool allows for the collection and assessment of ePROs with real-time graphical presentation of results to medical staff. Based on a predefined algorithm, automated alerts are sent to medical staff. Participating hematologists completed an online survey on their experience with the platform. Of the 201 patients invited to participate between December 2020 and June 2021 (cut-off date for current analysis), 180 (90%) agreed to enter the platform and had a median age of 57 years. Twenty-three hematologists with a median age of 42 years and an average of 17 years of experience in clinical practice were surveyed. All hematologists agreed or strongly agreed that the platform was easy to use, and 87%, agreed or strongly agreed that ePROs data were useful to enhance communication with their patients. The majority of physicians (78%) accessed the platform at least once per month to consult the symptom and health status profile of their patients. The frequency of access was independent of physician sex (p=0.393) and years of experience in clinical practice (p=0.404). In conclusion, our preliminary results support the clinical utility, from the perspective of the treating hematologist, of integrating ePROs into the routine cancer care of patients with hematologic malignancies.

Published
2022

Catalog

Books, media, physical & digital resources
See catalog results